BIOCERES CROP SOL.

Bioceres Crop Solutions reported Q4 FY2026 revenue of $55.9m, well below the analyst estimate of $79m, while adjusted EBITDA improved to $0.6m (prior year: -$9.6m). The company cut SG&A by 19% and achieved over $20m in operational cost savings, but recorded a full-year revenue decline of 18% to $238.0m. Management plans to focus on higher‑margin products, simplify the portfolio, monetize non‑core assets and strengthen debt management, but continues to see risks from legal disputes and limited liquidity. » Mere på de.investing.com

Bioceres reports a 23% revenue decline to $39.4m in Q3 FY2026, a net loss of $10.0m and adjusted EBITDA of -$0.6m. Results were well below analysts' expectations; EPS -$0.1572 versus forecast -$0.05, and the stock fell after hours to near its 52-week low. The Pro Farm foreclosure caused a cumulative loss of $179.0m and significant balance sheet adjustments, while the company cites cost cuts, a portfolio review, debt-restructuring talks and the appointment of Ezequiel Simmermacher as CFO as measures to stabilize the business. » Mere på de.investing.com

Bioceres Crop Solutions reported Q1 2025 revenue of $77.5m (−17% y/y) and EPS of −$0.1183, missing both revenue and earnings expectations by a wide margin. Gross margin rose to 47% and adjusted EBITDA climbed 61% to $13.6m, indicating operational efficiency despite declining sales. The company cites weak demand in Latin America, high net leverage and expects further revenue declines in the seeds segment, but anticipates a mid‑term recovery and positive effects from biostimulant sales to Corteva. The stock fell in after‑hours trading but showed slight recovery premarket. » Mere på de.investing.com

Bioceres Crop Solutions reported Q4 revenue of $74.7 million (‑40% year‑on‑year), missing the $111.68 million forecast by a wide margin. The stock fell about 14.98% in premarket trading to $2.27. Annual revenue declined 28% to $335.3 million; adjusted EBITDA dropped significantly, while operating cash flow rose 27%. The company is shifting its HB4 seed business to a license‑based model and now targets a 40% gross margin and a 22% EBITDA margin, and plans to cut costs and capital expenditures and strengthen the balance sheet. » Mere på de.investing.com

Bioceres will open the books on September 9, 2025, for the quarter ended June 30, 2025. Four analysts on average expect an EPS of 0.068 USD versus -0.020 USD a year earlier, but see revenue falling about 11.45% to an average of 110.1 million USD (prior year 124.3 million USD). For the recently completed fiscal year, analysts on average forecast a loss per share of -0.040 USD and revenue of 370.7 million USD versus 464.8 million USD in the prior year. » Mere på finanzen.net